Marinus Pharmaceuticals

Business news, market intelligence, and global industry analysis.

The Latest

Representative image illustrating an advanced AI system operating software autonomously, reflecting the Macrohard project unveiled by Tesla, Inc. and xAI, which Elon Musk claims could replicate the full operational functions of software companies using agentic artificial intelligence.

Macrohard : The AI project Musk says no other company can do yet, and what that claim actually means

United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF

Representative image illustrating a drone flying over California as reports reveal that Iran allegedly considered a surprise drone strike on targets in the state, according to a Federal Bureau of Investigation intelligence bulletin disclosed during the ongoing United States–Iran conflict.

Iran planned surprise drone strike on California, FBI bulletin reveals

Palantir Technologies (NASDAQ: PLTR) expands Asia enterprise push through LG CNS partnership

What LG CNS and Palantir’s new partnership means for the future of industrial AI adoption

Marinus Pharmaceuticals announces NMPA approval of Ganaxolone for CDKL5 deficiency disorder

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a leader in developing innovative therapeutics for seizure disorders, has achieved a significant milestone…

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

July 20, 2024